

UNIVERSITY OF LEEDS

This is a repository copy of *Ultrasensitive Detection of Clostridium difficile Toxins Reveals Suboptimal Accuracy by Toxin-Gene Cycle-Thresholds for Toxin Predictions.*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/146331/

Version: Accepted Version

Article:

Sandlund, J and Wilcox, MH orcid.org/0000-0002-4565-2868 (2019) Ultrasensitive Detection of Clostridium difficile Toxins Reveals Suboptimal Accuracy by Toxin-Gene Cycle-Thresholds for Toxin Predictions. Journal of clinical microbiology, 57 (6). e01885-18. ISSN 0095-1137

https://doi.org/10.1128/jcm.01885-18

© 2019 American Society for Microbiology. This is an author produced version of a paper published in Journal of clinical microbiology. Uploaded in accordance with the publisher's self-archiving policy.

Reuse
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/

1 **Ultrasensitive Detection of *Clostridium difficile* Toxins Reveals Suboptimal Accuracy by Toxin-Gene**

2 **Cycle-Thresholds for Toxin Predictions**

3 Johanna Sandlund[1], Mark H Wilcox[2]

4 [1]Singulex, Inc

5 [2]Leeds Teaching Hospitals NHS Trust and University of Leeds

6

7 **Corresponding author:**

8 Johanna Sandlund

9 Singulex, Inc.

10 1701 Harbor Bay Parkway Ste. 200

11 Alameda, CA 94502

12 Phone: 510.995.9076, Fax: 510.995.9092, Email: j.sandlund@singulex.com

13

14 **ABSTRACT**

15 The use of nucleic acid amplification tests (NAATs) for the diagnosis of *Clostridium* (*Clostridioides*)

16 *difficile* infection (CDI) leads to overdiagnosis. To improve the clinical specificity of NAATs, there has

17 been a recent interest in using toxin-gene cycle-thresholds (CT) to predict the presence and absence of

18 toxins. Although there is an association between CT values and fecal-toxin concentrations, the predictive

19 accuracy of the former is suboptimal for use in clinical practice. Ultrasensitive toxin immunoassays to

20 quantify free toxins in stool offer a novel option for high-sensitivity fecal-toxin detection, rather than

21 using surrogate markers for prediction.

22 **COMMENTARY**

23 Diagnosis and management of patients presenting with suspected *Clostridium* (*Clostridioides*) *difficile*
24 infection (CDI) can be complex. Diagnosis is based upon clinical presentation combined with a choice of
25 stool tests, including the detection of *C. difficile* toxins A (TcdA) and B (TcdB), which are the primary
26 virulence factors causing clinical disease, and molecular (nucleic acid amplification) tests, such as
27 polymerase chain reaction (PCR), which target a toxin gene. Recent advances have allowed for the
28 quantification of TcdA and TcdB as well as assessment of toxin gene load in diarrheal fecal samples from
29 patients with suspected CDI. When the concept of genomic load, determined by real-time PCR cycle
30 threshold (CT), was first put forward, preliminary data demonstrated promise for using this tool to
31 indirectly assess toxin load and hence to possibly predict disease severity and clinical outcomes (1–8).
32 Recently, studies using quantitative ultrasensitive toxin assays are questioning the clinical utility of PCR
33 beyond detection of toxin genes (9–11).

34

35 **Diagnostic Tools with Different Targets**

36 *C. difficile* infection (CDI) is a toxin-mediated disease and detection of free TcdA and/or TcdB in stool
37 correlates with outcome and severity (12, 13), but currently available toxin enzyme immunoassays (EIAs)
38 are hampered by poor sensitivity and lack of a quantitative readout. Also, assays measuring toxin in cell-
39 culture based assays (cell cytotoxicity neutralization assay; CCNA) are subjective and have a long
40 turnaround time (up to 48 hours). Detection of toxigenic organisms, either by nucleic acid amplification
41 tests (NAATs, such as PCR) or toxigenic culture, is insufficient for differentiation between CDI cases and
42 *C. difficile* carriers (who have symptoms not due to CDI) (12, 13). Notably, signs and symptoms in CDI
43 cases and *C. difficile* carriers overlap considerably, especially in hospitalized (usually elderly) patients

44 with multiple co-morbidities and many possible causes of diarrhea (14). Furthermore, none of these test
45 methods assess the quantity of toxin present.

46 Toxin EIAs were the mainstay of CDI diagnostics before NAATs for *C. difficile* toxin gene(s) became
47 commercially available in 2009 (15). For clinicians, who may have experienced missing cases using toxin
48 EIAs, NAATs offered a convenient rule-out of CDI. NAATs detect *C. difficile* organisms with the capacity
49 to produce toxin and have high negative predictive values, but their low clinical specificity has significant
50 effects on patient care and epidemiology.

51 Since the late 1990s, when CDI surveillance improved, incidence and severity of CDI cases have
52 increased (16). This has been attributed to various causes, such as outbreaks of hypervirulent strains and
53 increased transmission pressure, but also ascertainment bias (16). In parallel with the observed
54 increasing disease rates, molecular methods for detection of toxin genes were introduced to clinical
55 laboratories as a primary, first-line diagnostic tool. Reported CDI incidence increased rapidly, by up to
56 67% in certain regions, and >100% in individual healthcare centers, when testing methods changed from
57 toxin EIAs to NAATs (17). The mentioned factors attributable to risk for CDI may facilitate an increased
58 transmission, but cannot alone explain such dramatic changes in epidemiology. Reported disease
59 incidence varies with type of laboratory method used for diagnosis (16), and to avoid overdiagnosis, CDI
60 guidelines have recommended against using NAATs as standalone tests in unselected patient
61 populations (18, 19).

62

63 **PCR CT Values for Prediction of Toxin**

64 To expand the clinical utility of NAATs beyond the limitations associated with toxin-gene detection,
65 there has been a recent interest in determining whether real-time PCR CT values can predict the

66 presence or absence of *C. difficile* toxin. In a Dutch multicenter study, it was shown that patients with
67 NAAT-positive and toxin EIA-positive samples had lower *tcdB* CT values (hence higher genome load) than
68 subjects with NAAT-positive and toxin-negative stool. When using optimal CT cutoff values (25.3 and
69 27.0 in each of two study sub-cohorts) to estimate the accuracy of CT values for prediction of toxin EIA
70 status, the area under the receiver operating characteristic (AuROC) curves were 0.826 and 0.854,
71 respectively. Prediction of toxin EIA results was accurate for 78.9% and 80.5% of the samples in each
72 sub-cohort. The authors concluded that CT values could serve as predictors of toxin status, but noted
73 that additional toxin testing was still needed due to poor accuracy (1).

74 In another study, *tcdB* CT values were analyzed in PCR-positive samples reflexed to toxin EIA and CCNA.
75 Using EIA as the reference method, a *tcdB* CT cutoff of 26.4 detected toxin-positive samples with a
76 sensitivity, specificity, positive predictive value, and negative predictive value of 96.0%, 65.9%, 57.4%,
77 and 97.1%, respectively. Using both EIA and CCNA as the reference method (toxin present if either EIA
78 or CCNA is positive) , the specificity was improved to 78.0%. It was concluded that PCR may be used to
79 predict toxin-negative stool samples (2). Further analysis at the same institution showed that PCR-
80 positive patients with CT values above the cutoff had similar outcomes regardless of treatment status
81 (54 treated and 43 untreated), and that reporting of predicted toxin status based on CT value reduced
82 treatment of PCR-positive patients by 15%, with no increase in adverse outcomes (20).

83 When performing toxin-EIA testing in 1,650 PCR-positive patient samples, a *tcdB* Ct value of ≤26 was
84 associated with EIA positivity, higher mortality, and CDI severity (8). Seventy-two percent of patients
85 with CT values 18-21 had severe/recurrent CDI, and 59% of mild cases with CT values 18-21 had
86 treatment failure with first-line therapy. By contrast, 92% of the patients with CT values 35-37 had mild
87 CDI and responded to treatment. However, *tcdB* Ct values of ≤26 missed 28% of toxin-EIA positive

88 patients and the authors suggested that a CT of ≤26 could be used as an adjunct in CDI testing

89 algorithms and to guide reporting.

90 Other studies have demonstrated differences in *tcdB* CT values between groups positive and negative by

91 toxin EIA, and estimated toxin-EIA positivity with 79.3% sensitivity and 83.6% specificity (AuROC 0.848)

92 when using a cutoff of 26.3 (3). Using CCNA as reference method, *tcdB* CT values could predict 77% of

93 CCNA-positive cases in patients with cancer when using a CT cutoff of 28.0, and 91% and 100% of severe

94 and complicated CDI episodes, respectively (4). In addition, CT values in patients with CDI were

95 significantly lower than in excretors, i.e. patients with diarrhea who have toxigenic *C. difficile* in stool but

96 with no detectable free toxin (5). An inverse correlation between CT and *C. difficile* fecal loads

97 (Spearman -0.70), as estimated by using quantitative culture, has also been reported (6), as well as an

98 association between the amount of *C. difficile* present in the sample and the likelihood that toxins will

99 be detected directly (AuROC 0.921 for *tcdB* DNA copy number versus toxin result) (7), suggesting that CT

100 could be used as a surrogate marker for bacterial load and disease activity.

101

102 **Clinical Use of CT Values Concerning**

103 Scientists at King's College London also observed a significant correlation between *tcdB* CT values and

104 toxin-EIA positivity, but drew a more cautious conclusion regarding implementation in clinical practice

105 (21). In their study on over 1400 patients, CT values were lower in samples positive by toxin EIA

106 compared with toxin-negative samples, suggesting a higher organism load. The AuROC curve, 0.806, was

107 similar to the one generated by Kamboj *et al* (4), and the sensitivity and specificity were 83.1% and 67%,

108 respectively, at an optimal CT value threshold of 27.0. However, the authors observed a significant

109 overlap of CT values in those that were positive and negative by toxin EIA, and concluded that this made

110 it difficult in practice to use *tcdB* CT values to definitively categorize individual patients in this way (21).

In a study on 1,281 PCR-positive samples, a *tcdB* CT ≤25 was significantly associated with a toxin-positive result, as assessed using CCNA, with 51.3% sensitivity, 87.5% specificity, and 83.9% positive predictive value for presence of toxin (AuROC 0.831). CT values were lower in toxin-positive samples than in toxin-negative samples (median 24.9 vs 31.6) but did not differ between patients with or without a CDI recurrence. There was an association between both *tcdB* CT value and mortality and various signs of disease severity, and values were lower in patients who died than in survivors. The conclusions from the study were that due to the relatively low sensitivity and specificity for confirmation of detection of toxin, *tcdB* CT values cannot be used as a standalone test (22).

Studies estimating accuracy of CT values for toxin prediction use either toxin EIA or CCNA as references standards. Both tests have limitations, including poor analytical sensitivity and a non-quantitative format for toxin EIAs and a detection limited to primarily TcdB by CCNA. In addition, both tests have binary interpretations. With the advent of quantitative ultrasensitive toxin immunoassays, capable of quantification at very low concentrations, from picogram-per-millimeter levels (11, 15), an accurate assessment of toxin load can now be determined and the clinical value of using *tcdB* CT values to indirectly predict toxin can be further evaluated (9, 11, 15). In a recent study using PCR and an ultrasensitive toxin assay, multiple patients with CT values >26.4 had detectable stool toxin, including above analytical thresholds for EIA (~1000 pg/mL) and CCNA (TcdB of ~100 pg/mL) (10).

In a recent study using ultrasensitive Single Molecule Counting technology for toxin quantification (Singulex Clarity C. diff toxins A/B assay), there was also a significant inverse correlation between *tcdB* CT values and toxin concentrations (Spearman -0.64) in 211 patients with suspected CDI. However, 16 toxin-negative samples (<12.0 pg/mL) had *tcdB* CT values <27.0 (25.0% of all PCR+/toxin- samples), and 21 toxin-positive samples had CT values >27.0 (14.3% of all PCR+/toxin+ samples) (11). Similarly, in a recent study on 207 patients with PCR-positive samples, there were 18 samples toxin-negative by Clarity

with *tcdB* CT values <27.0 (22.8% of all PCR+/toxin- samples), and 36 toxin-positive samples with CT values >27.0 (14.3% of all PCR+/toxin+ samples) (9).

Possible Ways Forward

Guided by studies showing clinical utility, some laboratories may now consider implementing *C. difficile* toxin gene(s) CT values in CDI diagnostics, for prediction of free toxin and estimation of disease severity for treatment guidance. However, until the recent introduction of ultrasensitive toxin assays, no technology has been available for toxin measurements at picogram-per-milliliter levels. Presence and absence of *C. difficile* toxins have been defined by EIA or CCNA positivity. Thus, ultrasensitive immunoassays can be used to further evaluate the potential of *tcdB* CT values to predict the presence of fecal toxin. CT values, at the proposed cutoffs, do not detect all samples with high toxin concentration, not even those with very high concentration (above the EIA and CCNA cutoffs) (10). Although there is a correlation between *tcdB* CT values and toxin concentration, the accuracy is suboptimal for use in clinical practice. There is a significant risk of misclassifying patients and either treating incorrectly or inappropriately refraining from treatment. As reported in multiple studies using ultrasensitive toxin assays, a large proportion of patients with high toxin concentrations would have been misinterpreted as having undetectable toxin, if *tcdB* CT values had been used clinically. For many clinicians, such a high miss rate would be unacceptable.

It is important to note the contribution of host factors in a discussion about CDI diagnosis. We note that CDI and the influence of host factors have been established previously. Kyne *et al* showed that asymptomatic *C. difficile* carriers had high serum levels of toxin-A IgG, but that patients who became colonized by *C. difficile* but who had low levels of toxin-A IgG in serum had a much greater risk of CDI (23). The same group later showed that a serum antibody response to toxin A, during an initial episode

157 of CDI, was associated with protection against recurrence (24). Further studies are needed to

158 understand the clinical significance of both low and high toxin concentrations, as detected by

159 ultrasensitive assays. If toxins in low concentrations are deemed clinically meaningful, *tcdB* CT value

160 cutoffs based on low-sensitive toxin assays will not be useful. *tcdB* CT values as surrogate markers for *C.*

161 *difficile* toxin status provide unacceptable accuracy in terms of predicting toxin-positive patients in

162 studies using conventional EIAs or CCNA; such observations are reinforced by studies using ultrasensitive

163 toxin detection. Measurements of free toxins in stool can now be achieved at levels fulfilling the need

164 for both sensitivity and specificity. With the development of automated, ultrasensitive toxin assays, the

165 use of standalone NAATs and multistep algorithms in CDI diagnostics could potentially be replaced with

166 a single, direct test for free toxin.

167

168

169

170

171 **Conflict of Interest**

172 Johanna Sandlund is an employee of Singulex, Inc.

173 Mark Wilcox has provided consultancy advice to multiple CDI diagnostic companies, including Singulex,

174 Inc.

175 **References**

176 1. Crobach MJT, Duszenko N, Terveer EM, Verduin CM, Kuijper EJ. 2018. Nucleic Acid Amplification
177 Test Quantitation as Predictor of Toxin Presence in Clostridium difficile Infection. J Clin Microbiol
178 56.

179 2. Senchyna F, Gaur RL, Gombar S, Truong CY, Schroeder LF, Banaei N. 2017. Clostridium difficile PCR
180 Cycle Threshold Predicts Free Toxin. J Clin Microbiol 55:2651–2660.

181 3. Kim HN, Kim H, Moon H-W, Hur M, Yun Y-M. 2018. Toxin positivity and tcdB gene load in broad-
182 spectrum Clostridium difficile infection. Infection 46:113–117.

183 4. Kamboj M, Brite J, McMillen T, Robilotti E, Herrera A, Sepkowitz K, Babady NE. 2018. Potential of
184 real-time PCR threshold cycle (CT) to predict presence of free toxin and clinically relevant C.
185 difficile infection (CDI) in patients with cancer. J Infect 76:369–375.

186 5. Biswas JS, Patel A, Otter JA, van Kleef E, Goldenberg SD. 2015. Contamination of the Hospital
187 Environment From Potential Clostridium difficile Excretors Without Active Infection. Infect Control
188 Hosp Epidemiol 36:975–977.

189 6. Dionne L-L, Raymond F, Corbeil J, Longtin J, Gervais P, Longtin Y. 2013. Correlation between
190 Clostridium difficile Bacterial Load, Commercial Real-Time PCR Cycle Thresholds, and Results of
191 Diagnostic Tests Based on Enzyme Immunoassay and Cell Culture Cytotoxicity Assay. J Clin
192 Microbiol 51:3624–3630.

193 7. Leslie JL, Cohen SH, Solnick JV, Polage CR. 2012. Role of fecal Clostridium difficile load in
194 discrepancies between toxin tests and PCR: is quantitation the next step in C. difficile testing? Eur J
195 Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 31:3295–3299.

196 8. Garvey MI, Bradley CW, Wilkinson MAC, Holden E. 2017. Can a toxin gene NAAT be used to predict
197 toxin EIA and the severity of Clostridium difficile infection? Antimicrob Resist Infect Control 6.

198 9. Young S, Mills R, Griego-Fullbright C, Wagner A, Herding E, Nordberg V, Friedland E, Bartolome A,
199 Almazan A, Tam S, Bisocho S, Abusali S, Sandlund J, Estis J, Bishop JJ, Hansen G. Ultrasensitive
200 Detection of C. difficile Toxins in Stool Using Single Molecule Technology: A Multicenter Study for
201 Evaluation of Clinical Performance. IDWeek 2018.

202 10. Pollock NR, Banz A, Chen X, Williams D, Xu H, Cuddemi CA, Cui AX, Perrotta M, Alhassan E, Riou B,
203 Lantz A, Miller MA, Kelly CP. 2018. Comparison of Clostridioides difficile Stool Toxin Concentrations
204 in Adults with Symptomatic Infection and Asymptomatic Carriage using an Ultrasensitive
205 Quantitative Immunoassay. Clin Infect Dis. 68:78-86

206 11. Sandlund J, Bartolome A, Almazan A, Tam S, Biscocho S, Abusali S, Bishop J, Nolan N, Estis J, Todd J,
207 Young S, Senchyna F, Banaei N. 2018. Ultrasensitive Detection of C. difficile Toxins A and B Using
208 Automated Single Molecule Counting Technology. J Clin Microbiol. 56:e00908-18.

209 12. Polage CR, Gyorke CE, Kennedy MA, Leslie JL, Chin DL, Wang S, Nguyen HH, Huang B, Tang Y-W,
210 Lee LW, Kim K, Taylor S, Romano PS, Panacek EA, Goodell PB, Solnick JV, Cohen SH. 2015.
211 Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era. JAMA Intern Med
212 175:1792–1801.

213 13. Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, O'Connor L, Oakley SJ, Pope
214 CF, Wren MW, Shetty NP, Crook DW, Wilcox MH. 2013. Differences in outcome according to
215 Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C
216 difficile infection. Lancet Infect Dis 13:936–945.

217 14. Mawer D, Byrne S, Drake S, Brown C, Warne C, Bousfield R, Skittrall J, Wilcox M, West R, Sandoe J,
218 Kirby A, HOODINI Collaborators. 2017. Hospital-onset diarrhoea prevalence, aetiology and
219 management in the United Kingdom: the HOODINI study. Abstract OS0230. ECCMID 2017.

220 15. Pollock NR. 2016. Ultrasensitive Detection and Quantification of Toxins for Optimized Diagnosis of
221 Clostridium difficile Infection. J Clin Microbiol 54:259–264.

222 16. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. 2010.
223 The Changing Epidemiology of Clostridium difficile Infections. Clin Microbiol Rev 23:529–549.

224 17. Gould CV, Edwards JR, Cohen J, Bamberg WM, Clark LA, Farley MM, Johnston H, Nadle J, Winston
225 L, Gerding DN, McDonald LC, Lessa FC, Clostridium difficile Infection Surveillance Investigators,
226 Centers for Disease Control and Prevention. 2013. Effect of nucleic acid amplification testing on
227 population-based incidence rates of Clostridium difficile infection. Clin Infect Dis Off Publ Infect Dis
228 Soc Am 57:1304–1307.

229 18. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW,
230 Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. 2018. Clinical Practice
231 Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious
232 Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).
233 Clin Infect Dis Off Publ Infect Dis Soc Am.

234 19. Crobach MJT, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, Wilcox MH, Kuijper EJ. 2016.
235 European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic
236 guidance document for Clostridium difficile infection. Clin Microbiol Infect Off Publ Eur Soc Clin
237 Microbiol Infect Dis 22 Suppl 4:S63-81.

238 20. Hitchcock M, Holubar M, Tompkins L, Banaei N. Tuning Down PCR Sensitivity Reduces Treatment
239 for Clostridioides difficile Infection in Toxin-Negative Patients With No Increase in Adverse
240 Outcomes. Poster 1092, IDWeek, 2018.

241 21. Wilmore S, Goldenberg SD. 2018. Potential of real-time PCR threshold cycle (CT) to predict
242 presence of free toxin and clinically relevant C. difficile infection (CDI) in patients with cancer: A
243 reply. J Infect 76:424–426.

244 22. Davies K, Wilcox M, Planche T. 2018. The predictive value of quantitative nucleic acid amplification
245 detection of Clostridium difficile toxin gene for faecal sample toxin status and patient outcome (in
246 press). PLOS ONE.

247 23. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and
248 serum levels of IgG antibody against toxin A. N Engl J Med 342:390–397.

249 24. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and
250 protection against recurrent Clostridium difficile diarrhoea. Lancet Lond Engl 357:189–193.

251